News

Company News: Curetis Reports Results of the Annual Shareholder Meeting Held on June 23, 2017

– Dr. Nils Clausnitzer elected as member of the Supervisory Board

Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today reported the results of its Annual Shareholder Meeting (“AGM”) held in Amsterdam on June 23, 2017.

The shareholders approved all items on the agenda of the AGM, including the election of Dr. Nils Clausnitzer (Senior Vice President and President EMEA-APAC Lab and Distribution Services of VWR International llc./ VWR GmbH, Germany) as a member of Curetis´ Supervisory Board for a three-year term until 2020. Nils Clausnitzer has profound knowledge in sales and marketing of diagnostics and medical products. Prior to VWR International, he was President and Head of Commercial Operations, EMEA at Qiagen N.V. and General Manager for Olympus Germany. He also worked as Managing Director for Abbott Diagnostics Germany.

Moreover, Dr. Holger Reithinger and Dr. Rudy Dekeyser were re-elected for another one-year term, respectively. In addition, the proposed extension of authorization of the Management Board to limit or exclude pre-emptive rights on newly issued shares or rights to subscribe for shares as well as an extension of authorization of the Management Board to repurchase shares were also approved by the shareholders.

“We are excited to have Nils Clausnitzer on our board,” said Oliver Schacht, CEO of Curetis. “He brings unparalleled expertise in the commercialization of molecular diagnostics and medical products and deep market knowledge coupled with his medical background to Curetis. Nils Clausnitzer will play a key role in helping Curetis drive its commercial rollout. Moreover, we are pleased that all proposed AGM resolutions have been approved with big majorities by our shareholders.”